ClinicalTrials.gg
TerminatedNCT05146492EPERICARDIMUpdated Jul 16, 2026

Pericardial Effusion From Acute Myocardial Infarction: Contributing Factors and Prognosis at One Year (EPERICARDIM)

An interventional study of MRI in Acute Myocardial Infarction and Pericardial Effusion, sponsored by GCS Ramsay Santé pour l'Enseignement et la Recherche. Terminated at 1 site in France. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-07-16.

Sponsored by GCS Ramsay Santé pour l'Enseignement et la Recherche · Not applicable, Interventional, and Health services research

Why this study was terminated
recruitment difficulty

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Jul 2021, registered Nov 2021).
Phase
Not applicable
Study type
Interventional
Enrollment
3
Allocation
Non-randomized
Ages
18 Years to 90 Years
Sex
All
01

Study summary

This study aims to clarify, in patients with more or less abundant pericardial effusion in the acute phase of a myocardial infarction, the correlation between the existence of this effusion during the acute phase with clinical parameters, biological, angiographic, therapeutic and with transmurality, extent, microvascular obstruction and intra myocardial hemorrhage found on MRI made beyond one week and before the 3rd month of the constitution of the necrosis.

02

Conditions studied

  • Acute Myocardial Infarction
  • Pericardial Effusion

Browse trials for

03

In context

Pericardial Effusion

29 studies on the registry are indexed under Pericardial Effusion; 5 are open to participants now.

This study's enrollment of 3 is below the median of 111 across 23 interventional studies indexed under Pericardial Effusion.

Browse Pericardial Effusion studies →

Lead sponsor

GCS Ramsay Santé pour l'Enseignement et la Recherche is the lead sponsor of 207 studies on the registry; 99 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient between 18 and 90 years old
  • Patient admitted to the acute or semi-recent phase (within the next fifteen days) of a myocardial infarction (primary or recurrent myocardial infarction) documented by a significant enzymatic release of troponin (threshold value at 100) in the course of: chest pain or shock, or flare-up of heart failure (left or global) or successfully resuscitated cardiac arrest, or paroxysmal ventricular arrhythmia with or without sus shift of the ST segment on the input trace, with or without Q wave of necrosis formed. This IDM may or may not be complicated by a more or less abundant pericardial effusion of more than 10 mm in the left parasternal, which may in the extreme be the cause of tamponade;
  • Subject affiliated or beneficiary of a social security scheme;
  • Patient having signed the free and .

Exclusion criteria

Exclusion Criteria:

  • Patient with a pericardial detachment of less than 10 mm, or only systolic;
  • Patient who had a break-in during the primary angioplasty guide or complicated coronary dissection extravasation with secondary pericardial effusion;
  • Patient with advanced chronic renal failure
  • Patient unable to perform an MRI (with a defibrillator or pacemaker).
  • Known allergy to contrast agents, in particular gadolinium
  • claustrophobic patient;
  • Protected patient: adult under guardianship or other legal protection, deprived of liberty by judicial or administrative decision;
  • Pregnant or breastfeeding woman;
  • Patient hospitalized without consent.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Active comparator
    Patient with acute myocardial infarction without pericardial effusion

    Procedure: MRI

  • Experimental
    Patient with acute myocardial infarction and pericardial effusion

    Procedure: MRI

Interventions

  • ProcedureMRI

    MRI with gadolinium contrast media injection

06

What researchers measure

Primary outcomes

  1. One-year mortality rate of patients with pericardial effusion

    One-year mortality rate of patients with pericardial effusion

    Time frame: 1 year

07

Study locations

1 site
  • Private Hospital of Parly II-Le Chesnay
    Le Chesnay, 78150, France
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05146492
Collaborators
European Clinical Trial Experts Network
Responsible party
Sponsor
First posted
Dec 6, 2021
Start date
Jul 19, 2021
Primary completion
Jan 31, 2024
Completion
Feb 29, 2024
Last update
Jul 16, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion